Clinical Trial Update: Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease [Phase 1]

View source ↗

Summary

Roche completed a Phase 1 biomarker study in early manifest Huntington's disease to measure cerebrospinal fluid mutant huntingtin protein; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Huntington's Disease | Phase 1 | Status: COMPLETED | Results posted: 2025-01-03